Teva Pharmaceutical Industries

Teva fined €463M by EU antitrust enforcer for smear campaign against rival MS drug, misusing patent system to block market entry.

Alvotech and Teva announced FDA approval for SELARSDI™ (ustekinumab-aekn) in a new 130 mg/26 mL IV infusion format, expanding its use to match STELARA®'s indications. SELARSDI™, previously approved for subcutaneous injection, is set for U.S. launch in early 2025, aiding gastrointestinal disease patients.

Teva fined 462.6 million euros by EU for abusing dominant position to delay competition to MS drug Copaxone; Teva plans to appeal.

Alvotech and Teva receive FDA clearance for Selarsdi (ustekinumab-aekn) 130 mg/26 ml, aligning its label with Stelara's indications in the U.S. prior to its 2025 launch. The approval follows successful biosimilar ustekinumab launches in Canada, Japan, and Europe, reflecting the companies' commitment to increasing access to biosimilars globally.

AION Labs launches ProPhet, an AI-driven startup focusing on identifying active small molecules for drug discovery, aiming to reduce time and cost by targeting challenging proteins.

UK health secretary announces £279 million for weight-loss jab trials, aiming to tackle obesity crisis. Key drugs like Wegovy and Mounjaro are seen as crucial, though concerns exist over side effects and misuse. The drugs mimic GLP-1 hormone to control blood sugar and signal fullness, with Mounjaro targeting both GLP-1 and GIP receptors for enhanced weight loss. Despite potential, experts emphasize these treatments are not a 'silver bullet' and should be combined with dietary interventions and policy changes.

The Anxiety Disorders and Depression Treatment Market was valued at USD 12.2 billion in 2023 and is projected to reach USD 16.65 billion by 2032, growing at a CAGR of 3.53%. This growth is driven by the rising prevalence of anxiety disorders and depression, advancements in pharmaceutical therapies, and increased awareness and destigmatization of mental health issues.

Teva and mAbxience announce a global licensing agreement for the development of an anti PD-1 oncology biosimilar, marking their second collaboration. mAbxience will lead development and production, while Teva will manage regulatory approvals and commercialization, aiming to provide cost-effective, high-quality biosimilar treatments globally.